Eric
Delbridge

There is a particular kind of investor who sees biotech the way a cardiologist reads an EKG - not pattern-matching financial signals but reading the biological story underneath. Eric Delbridge is that investor. He is also, depending on how you count, a doctor who never practiced medicine, a hedge fund operator who crossed into venture capital, and one of the few people on Sand Hill Road who spent their undergraduate years translating Cicero.

Delbridge graduated from Yale with a B.A. in Classics - cum laude, a small distinction that signals something about how seriously he took the work. He then earned his M.D. from Northwestern University before pivoting sharply: no residency, no clinical career, instead a move into investment banking at Credit Suisse and Lazard, where he spent his early career advising on biotech mergers and acquisitions.

The Wharton School followed. He graduated as a Palmer Scholar - a designation given to the top 5% of the MBA class - and went straight back into the industry he had already started mapping. The credentials accumulate in a way that looks, in retrospect, inevitable.

What that MD actually buys him in the investing world is worth slowing down on. Most biotech analysts learn to read clinical trial data the way someone learns a foreign language from a textbook - functional, technically correct, but missing the native intuition. Delbridge has the native intuition. He knows the pharmacology at the level of mechanism. When a company reports a trial readout, he understands what the protocol design implies about what the sponsor believed they were testing. That is a different kind of edge.

Before joining Sofinnova in 2016, Delbridge spent the better part of a decade in the hedge fund world - a training ground that most venture capitalists skip entirely, and whose absence often shows.

He joined Spring Point Capital, formerly known as Botti Brown Asset Management, as a Partner. It was a long/short equity hedge fund with a focused healthcare mandate - the kind of shop where position sizing, risk management, and short conviction matter as much as identifying winners. Running a short book in biotech is a discipline that forces brutal honesty about thesis quality. You do not short stocks casually in a sector where a single trial readout can move a name 60% overnight.

From Spring Point, he moved to Balyasny Asset Management, one of the larger multi-strategy hedge funds in the world. There, he ran market neutral therapeutics and healthcare portfolios - a strategy that requires building both long and short books simultaneously, hedging out sector and factor exposure to isolate stock-specific alpha. It is as technically demanding as investing gets, and it trains a certain coldness about company stories that pure venture investors rarely develop.

These years matter because they explain what Delbridge brought to Sofinnova that was genuinely new. The firm - founded in 1976 and one of the oldest dedicated biotech venture operations in the country - had deep private market expertise. What it did not have was a systematic approach to the public side. Delbridge was recruited to build exactly that.

When Delbridge joined Sofinnova in 2016, he was given a mandate with no exact precedent at the firm: build a public equity strategy that complements the private venture business. Three years later he was General Partner. That timeline - portfolio manager to GP inside three years - says something about how the execution landed.

The Sofinnova BioEquities strategy now manages approximately $1.5 billion. It is a long/short approach focused on global therapeutics companies, an area where Delbridge's hedge fund background and clinical training converge most directly. The fund sits at an unusual position in the market: it has access to Sofinnova's private company intelligence, relationships with management teams, and understanding of the competitive landscape - all information sources that typical public-only funds cannot replicate.

The broader Sofinnova platform has a track record that gives the public strategy a meaningful foundation. Since 1976, the firm has funded 118 companies, facilitated 55 IPOs, and seen 30 companies acquired. Those exits represent the full arc of the biotech development cycle - early science, clinical maturation, approval, and commercial success. Delbridge is watching the same pipeline at its public market inflection points.

The fund concentrates on companies in areas of high unmet medical need - oncology, respiratory disease, neurology, ophthalmology, dermatology, and women's health. The focus on diseases where existing treatments fall short is both a moral and commercial conviction: those are the markets where premium pricing is justified, regulatory pathways are often accelerated, and patient demand is durable.